Close
  • Home

CAR-T Digest - August 2020

CAR-T Digest - August 2020

CAR-T Digest - August 2020

CAR-T Digest - August 2020

Funding

Approval  ·  Weekly Digest - 17 January to 23 January 2026
ENHERTU approved in China as the first and only HER2 directed ADC for the second-Line treatment of patients with HER2 positive metastatic gastric cancer

Weekly Digest – January 2026 Weekly Digest – January 2026 22 January 2026: ENHERTU approved in China as the first and only HER2 directed ADC for the second-Line treatment of patients with HER2 positive metastatic gastric cancer  ENHERTU (trastuzumab deruxtecan) has been approved in China for the second-line treatment of adults with […]

by Sandhya Ramalingam

Continue Reading
Approval  ·  Weekly Digest - 17 January to 23 January 2026
Daiichi Sankyo Korea and AstraZeneca Korea receive approval for Enhertu for patients with HER2 low- and ultra-low-expression metastatic breast cancer treated with endocrine therapy

Weekly Digest – January 2026 Weekly Digest – January 2026 21 January 2026: Daiichi Sankyo Korea and AstraZeneca Korea receive approval for Enhertu for patients with HER2 low- and ultra-low-expression metastatic breast cancer treated with endocrine therapy  Daiichi Sankyo Korea and AstraZeneca Korea announced that Enhertu (trastuzumab deruxtecan) has received approval from Korea’s Ministry of Food […]

by Sandhya Ramalingam

Continue Reading
Regulatory  ·  Weekly Digest - 17 January to 23 January 2026
Lilly’s sofetabart mipitecan receives U.S. FDA’s Breakthrough Therapy designation for the treatment of certain patients with platinum-resistant ovarian cancer

Weekly Digest – January 2026 Weekly Digest – January 2026 20 January 2026: Lilly’s sofetabart mipitecan receives U.S. FDA’s Breakthrough Therapy designation for the treatment of certain patients with platinum-resistant ovarian cancer Eli Lilly announced that the U.S. FDA has […]

by Sandhya Ramalingam

Continue Reading
Regulatory  ·  Weekly Digest - 17 January to 23 January 2026
Sichuan Baili Tianheng Pharmaceutical’s BL-B01D1 marketing application (NDA) has been formally accepted by China’s National Medical Products Administration (NMPA)

Weekly Digest – January 2026 Weekly Digest – January 2026 21 January 2026: Sichuan Baili Tianheng Pharmaceutical’s BL-B01D1 marketing application (NDA) has been formally accepted by China’s National Medical Products Administration (NMPA) Sichuan Baili Tianheng Pharmaceutical announced that China’s National […]

by Sandhya Ramalingam

Continue Reading
Regulatory  ·  Weekly Digest - 17 January to 23 January 2026
Avacta announces U.S. Food and Drug Administration clearance of the Investigational New Drug (IND) application for the second pre|CISION medicine, FAP-Exatecan (AVA6103)

Weekly Digest – January 2026 Weekly Digest – January 2026 21 January 2026: Avacta announces U.S. Food and Drug Administration clearance of the Investigational New Drug (IND) application for the second pre|CISION medicine, FAP-Exatecan (AVA6103) Avacta Therapeutics announced that the U.S. […]

by Sandhya Ramalingam

Continue Reading
Deals  ·  Weekly Digest - 17 January to 23 January 2026
Ellipses in-licenses first-in-class B7H3 Antibody Drug Conjugate from China

Weekly Digest – January 2026 Weekly Digest – January 2026 19 January 2026: Ellipses in-licenses first-in-class B7H3 Antibody Drug Conjugate from China Ellipses Pharma announced that it has entered into a collaboration and licensing agreement with Innolake Biopharm to in-license […]

by Sandhya Ramalingam

Continue Reading
Regulatory  ·  Weekly Digest - 10 January to 16 January 2026
The Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA) has included SHR-1826 in its list of breakthrough therapies for non-squamous non-small cell lung cancer with c-Met overexpression

Weekly Digest – January 2026 Weekly Digest – January 2026 12 January 2026: The Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA) has included SHR-1826 in its list of breakthrough therapies for non-squamous non-small cell lung […]

by Sandhya Ramalingam

Continue Reading
Regulatory  ·  Weekly Digest - 10 January to 16 January 2026
SK Biopharm wins FDA approval for Phase 1 trial of alpha-emitter cancer therapy

Weekly Digest – January 2026 Weekly Digest – January 2026 12 January 2026: SK Biopharm wins FDA approval for Phase 1 trial of alpha-emitter cancer therapy SK Biopharm announced that it has received U.S. FDA approval for an investigational new […]

by Sandhya Ramalingam

Continue Reading
Clinical  ·  Weekly Digest - 10 January to 16 January 2026
TROPION-Lung17 TROP2 biomarker directed Phase 3 trial of DATROWAY initiated in patients with previously treated advanced nonsquamous non-small cell lung cancer

Weekly Digest – January 2026 Weekly Digest – January 2026 13 January 2026: TROPION-Lung17 TROP2 biomarker directed Phase 3 trial of DATROWAY initiated in patients with previously treated advanced non-squamous non-small cell lung cancer The first patient has been dosed […]

by Sandhya Ramalingam

Continue Reading
Deals  ·  Weekly Digest - 10 January to 16 January 2026
Summit Therapeutics announces clinical trial collaboration with GSK to evaluate Ivonescimab in combination with GSK’s B7-H3 antibody drug conjugate (ADC)

Weekly Digest – January 2026 Weekly Digest – January 2026 12 January 2026: Summit Therapeutics announces clinical trial collaboration with GSK to evaluate Ivonescimab in combination with GSK’s B7-H3 antibody drug conjugate (ADC) Summit Therapeutics announced a clinical trial collaboration […]

by Sandhya Ramalingam

Continue Reading
« First‹ Previous232425262728293031Next ›Last »
Page 27 of 63


Contact:

  info@ciscientists.com

 +1-908-212-7484

Optimal Dose

For a subscription, please provide your email id